Bioceros awarded GO EFRO grant in consortium led by Synthon

27-Sep-2012 - Netherlands

Bioceros BV announced that it participates in the ACCESS project consortium led by Synthon, which has been awarded a grant within the GO EFRO program. The budget of almost €1 million is available for the development of improved antibody manufacturing systems. Other partners in this consortium are IBIS Technologies BV, Infors Benelux BV and Wageningen University (The Netherlands).

Louis Boon, CSO of Bioceros, said: "This collaboration builds on Bioceros’ capabilities in cell line generation and antibody manufacturing, where we consistently produce monoclonal antibodies at titers of multiple grams per liter in bioreactors. The consortium with its broad expertise will further integrate cell line generation and process development to reduce development timelines. I look forward to a fruitful collaboration.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous